Changes in Posttreatment Spleen Volume Associated with Immunotherapy Outcomes for Advanced Hepatocellular Carcinoma
DOI: https://doi.org/10.2147/jhc.s462470
2024-06-05
Journal of Hepatocellular Carcinoma
Abstract:Bang-Bin Chen, 1, 2 Po-Chin Liang, 1– 3 Tiffany Ting-Fang Shih, 1, 2 Tsung-Hao Liu, 4– 6 Ying-Chun Shen, 4– 6 Li-Chun Lu, 4– 6 Zhong-Zhe Lin, 4, 6 Chiun Hsu, 4– 6 Chih-Hung Hsu, 4– 6 Ann-Lii Cheng, 4– 7 Yu-Yun Shao 4– 6 1 Department of Medical Imaging, National Taiwan University Hospital, Taipei City, Taiwan; 2 Department of Radiology, College of Medicine, National Taiwan University, Taipei City, Taiwan; 3 Department of Medical Imaging, National Taiwan University Hospital Hsin-Chu Branch, Hsin-Chu City, 300, Taiwan; 4 Department of Oncology, National Taiwan University Hospital, Taipei City, Taiwan; 5 Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei City, Taiwan; 6 Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan; 7 Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan Correspondence: Yu-Yun Shao, Department of Oncology, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei City, 100, Taiwan, Tel +886-2 23123456 ext. 66008, Fax +886-2 23711174, Email Purpose: We investigated whether spleen volume (SV) changes were associated with treatment outcomes in advanced hepatocellular carcinoma (HCC) patients who received immunotherapy or first-line sorafenib. Patients and Methods: Patients with advanced HCC who underwent immunotherapy or first-line sorafenib at our institute were retrospectively analyzed. CT was used to measure SV before and within 3 months of treatment initiation. Tumor assessment followed Response Evaluation Criteria in Solid Tumors version 1.1. The association between SV change and tumor response or progression-free survival (PFS) was analyzed. The inverse probability of treatment weighting (IPTW) was used to adjust for differences in baseline characteristics. Results: The immunotherapy group comprised 143 patients (124 men, mean age, 59.8 years ± 11.2 [standard deviation]), while the sorafenib group had 57 (47 men, mean age, 59.6 years ± 9.9). SV increased in 108 (75.5%) immunotherapy and 21 (36.8%) sorafenib patients. In the immunotherapy group, patients with increased SV were more likely than those with decreased SV to have a higher disease control rate (76.9% vs 57.1%, p = 0.024) and durable clinical benefit (52.8% vs 25.7%, p = 0.005). It was also associated with extended PFS in the immunotherapy group in both the univariate ( p = 0.028) and multivariate ( p = 0.014) analysis. By contrast, in the sorafenib group, an increased in SV was not associated with treatment response but was presumably associated with reduced PFS ( p = 0.072) in the multivariate analysis. After IPTW adjustment, the increase in SV remained a significant predictor for DCB and PFS in the immunotherapy group. Conclusion: Most patients exhibited an increase in SV after the initiation of immunotherapy, which may be used to predict response and prognosis. However, this association was not observed in patients who received sorafenib. Plain Language Summary: The study provides significant evidence that an increase in spleen volume is associated with better treatment outcomes in advanced hepatocellular carcinoma patients undergoing immunotherapy. These findings offer oncologists a new potential biomarker for optimizing treatment strategies. Specifically, increased spleen volume could be used to predict higher rates of disease control and durable clinical benefits, allowing for more personalized care. Keywords: hepatocellular carcinoma, immunotherapy, sorafenib, response, survival Graphical Hepatocellular carcinoma (HCC) remains a substantial global health concern because of its increasing incidence and limited therapeutic options, especially in its advanced stages. 1 Sorafenib is a potent multikinase inhibitor that was first introduced as a standard first-line treatment in two Phase III clinical trials. 2,3 Recently, immune checkpoint inhibitors (ICIs) have revolutionized the treatment methods for HCC. Compared with standard systemic therapy, combination therapy involving ICIs has demonstrated improved survival rates in patients with advanced HCC. 4–8 However, not all patients benefit from ICIs. 9 Therefore, reliable markers are urgently required to facilitate treatment selection and monitor therapeutic response. 10,11 Many biomarkers that are potentially useful in predicting the treatment efficacy of ICIs in other types of cancer do not exhibit a similar efficacy in advance -Abstract Truncated-
oncology